Novartis announces the safety and efficacy profile of Aimovig


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ novartis-announces-five-year-data-reinforce-safety-efficacy-profile-aimovig-adult-patients-episodic-migraine
Five-year open-label extension study shows patients continued to experience a sustained benefit; Aimovig maintained a consistent safety profile

Novartis today announced that results reinforcing the long-term safety and efficacy profile of Aimovig (erenumab-aooe) in patients with episodic migraine (EM) are being presented at the Migraine Trust Virtual Symposium. Results from the five-year, open-label treatment period of a Phase 2 study in episodic migraine prevention showed Aimovig helped patients achieve sustained reductions in monthly migraine days (MMD) and in use of acute migraine-specific medication, such as triptans. Additionally, the safety profile was consistent with what was observed in the double-blind treatment phase of the study, with no increases in adverse event rates over five years of exposure.1

"These important data highlight the sustained efficacy, safety and tolerability profile of Aimovig, and provide crucial information for patients and doctors managing migraine," said Dr Messoud Ashina, Professor of Neurology in the Faculty of Health and Medical Sciences at the University of Copenhagen. "The study reinforces the potential of Aimovig to reduce monthly migraine days over the long term for people living with this debilitating, yet underdiagnosed disease. For my patients, more migraine-free days means they're able to get back to the things that are important to them, like spending more time with family and friends, and being able to go to work."

The five-year, open-label treatment phase enrolled 383 patients with episodic migraine who completed a 12-week double-blind, placebo-controlled treatment period (DBTP). Among the 216 patients who completed the open-label treatment phase, there was an average MMD reduction of 5.3 days from the DBTP baseline of 8.7 days. By the end of the study, patients who used AMSM to treat their migraine headaches experienced an average reduction in AMSM use of 4.4 days from the DBTP baseline of 6.2 days. The most common side effects were nasopharyngitis, upper respiratory tract infection and influenza.

"These long-term results signify a big step for people affected by this debilitating neurological disease, many of whom live in dread of the next attack, and demonstrate progress for the millions of patients who may be candidates for preventive migraine treatment," said Victor Bultó, President, Novartis Pharmaceuticals Corporation. "As the first FDA-approved treatment and most prescribed preventive therapy in the calcitonin gene-related peptide class of medications, Aimovig represents Novartis' strong heritage and ongoing commitment to research and development to better support patients."

Additional studies highlighting Aimovig will be presented at the Migraine Trust Virtual Symposium, including interim results of the LIBERTY open-label extension study as well as efficacy and safety results of Aimovig in the EMPOwER study. These studies reinforce the efficacy and safety profile of Aimovig for patients of various backgrounds across the episodic migraine spectrum.

Tags : #Novartis #USFDAApprovedMedicineforMigraine #LatestPharmaNews0310 #VictorBult #DrMessoudAshina

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Patient Safety Is a Business Priority for Indian HospitalsNovember 10, 2026
Reducing ED Wait Times Through Smarter Hospital DesignNovember 10, 2026
Maternal Mental Health: Integrating Emotional Wellbeing Into Postnatal CareNovember 10, 2026
Occupational Health for Healthcare Workers: Preventing Musculoskeletal StrainNovember 10, 2026
Sleep Health in India: Recognising the Public Health Impact of Sleep DisordersNovember 06, 2026
Childhood Hearing Screening: Linking Early Detection With Timely SupportNovember 06, 2026
Low-Dose Imaging in India: Accuracy Meets SafetyNovember 06, 2026
Synthetic Health Data: Powering the Future of Medical AINovember 06, 2026
AI and Clinical Trials: How ML Is Changing Patient RecruitmentNovember 05, 2026
Photon-Counting CT: What Indian Hospitals Need to KnowNovember 05, 2026
Rare Diseases in India: Navigating Diagnosis, Support and Long-Term CareNovember 05, 2026
Oral Health and Systemic Health: The Case for Routine Dental IntegrationNovember 05, 2026
KIMS Hospitals Takes Another Major Step Forward in Cancer Care with Advanced TrueBeam TechnologyNovember 04, 2026
SRM Medical College Hospital and Research Centre Hosts National Conference on Translational Regenerative Biology and Bioengineering – TRBB 2026November 04, 2026
15-Month-Old Russian Baby Avoids Lung Transplant Following Treatment at MGM HealthcareNovember 04, 2026
Why Diabetes Care Must Go Beyond Blood Sugar ControlNovember 04, 2026
Sri Sathya Sai Heart Hospital Successfully Organises Free Heart Camp, Screening for 550 Patients in Dehradun, UttarakhandNovember 04, 2026
Expert Quote | Rising Air Pollution in Delhi | Agilus DiagnosticsNovember 04, 2026
Healthcare AI Safety Officers: India's New Leadership NeedNovember 04, 2026
Next-Generation Medical Imaging: Beyond Traditional ScansNovember 04, 2026